ProCE Banner Activity

Phase Ib Trial of Venetoclax, Lenalidomide, and Rituximab in Untreated Mantle Cell Lymphoma

Slideset Download
Conference Coverage
Addition of venetoclax to lenalidomide and rituximab in untreated MCL was well tolerated and showed early evidence of high response rates and undetectable MRD.

Released: June 16, 2021

Expiration: June 15, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme